A recent study reveals that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Findings released in a leading health publication points out that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users buying such drugs should be aware of the potential of rapid weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight in about 18 months.
Weighing Approaches
The study, which reviewed 37 of trials involving thousands of patients, compared the effects of these new drugs with other pills.
Scientists note that people who shed pounds through diet and exercise generally have a less rapid weight regain—around 100 grams monthly—after stopping.
Understanding the Fast Rebound
Experts suggest the way of the jabs accounts for the accelerated rebound.
The injections imitate a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
Medical guidelines recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, given the likelihood of relapse, the therapy might need to be ongoing.
This perspective is reinforced by drug manufacturers, who state that the results "highlight the long-term character of excess weight," similar to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the jabs describe a powerful return of hunger.
"It felt as if something flipping and you become starving," recalled a patient.
This difficulty is exacerbated if patients have not developed lasting lifestyle or habit modifications during treatment.
Growing Interest
Survey data suggest that millions of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians stress that while the jabs are potent agents for weight loss, they are not a permanent cure and long-term success likely depends on combined behavioural support.
